Skip to main content
SpringerLink
Log in
Book cover

Drug-Induced Hepatotoxicity

  • Book
  • © 1996

Overview

Editors:
  1. Ross G. Cameron

    1. Department of Pathology Division of Experimental Pathology, University of Toronto, Toronto, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. George Feuer

    1. Department of Clinical Biochemistry Banting Institute, University of Toronto, Toronto, Canada

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Felix A. Iglesia

    1. Parke-Davis Pharmaceutical Research Division Department of Pathology and Experimental Toxicology, Warner Lambert Company, Ann Arbor, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 121)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (26 chapters)

  1. Front Matter

    Pages I-XXXI
    Download chapter PDF

  2. Orientation in Liver Toxicity by Drugs

    • E. Farber
    Pages 1-23

  3. Clinical Studies and Role of Necrosis in Hepatotoxicity

    • R. G. Cameron, L. M. Blendis
    Pages 25-42

  4. Subcellular Biochemical and Pathological Correlates in Experimental Models of Hepatotoxicity

    • G. Feuee, F. A. Iglesia
    Pages 43-73

  5. Molecular Biology of Hepatic Drug Reactions

    • R. W. Sallie, E. A. Jones
    Pages 75-97

  6. In Vitro Models of Liver Toxicity

    • R. G. Thurman, P. E. Ganey, S. A. Belinsky, J. G. Conway, M. Z. Badr
    Pages 99-117

  7. Cytochromes P450 and Liver Injury

    • J. S. Leeder, A. B. Okey
    Pages 119-153

  8. Mechanisms of Drug-Induced Cholestasis

    • J. B. Watkins III, C. D. Klaassen
    Pages 155-171

  9. Fatty Liver and Drugs

    • M. U. Dianzani
    Pages 185-210

  10. Choline Deficiency: An Important Model for the Study of Hepatotoxicity

    • A. K. Ghoshal
    Pages 211-220

  11. Immune Mechanisms and Liver Toxicity

    • I. R. MacKay
    Pages 221-247

  12. Hepatic Encephalopathy

    • A. S. Basile
    Pages 249-271

  13. Liver Drug Reactions and Pregnancy

    • F. Trevisani, D. H. van Thiel
    Pages 273-292

  14. Pediatric Hepatic Drug Reactions

    • E. A. Roberts
    Pages 293-322

  15. Reye’s Syndrome

    • R. R. Varma
    Pages 323-340

  16. Drug Hepatotoxicity in the Elderly

    • K. Kitani
    Pages 341-366

  17. Effect of Liver Disease on Drug Metabolism and Pharmacokinetics

    • P. G. Welling, W. F. Pool
    Pages 367-394

  18. Liver Reactions to Tacrine

    • T. F. Woolf, W. P. Pool, R. M. Walker, D. K. Monteith
    Pages 395-410

  19. Mechanisms of Hypertransaminemia

    • M. Pirmohamed, B. K. Park
    Pages 411-440

  20. Diagnostic Tools and Clinical Pathology

    • D. C. Snover
    Pages 441-455
Back to top

Keywords

About this book

The advances in science and medicine we are now experiencing are unprec­ edented and exciting. Life expectancy is prolonged, and quality of life is much improved. We learn of fabulous new discoveries made at the bench or the bedside every week. Many diseases have been totally eliminated, others can be significantly improved by new therapeutic formulations. Much of the success can be attributed to a better understanding of disease processes and the specific targeting of new and more effective medications. As is the case in many areas of successful human endeavour, there can be a downside. In the case of drugs and chemicals it is their adverse effects which are of concern. Of course, every effort is made to devise medications that are safe, and the need to elucidate and understand mechanisms are crucial, yet adverse effects remain a problem. They can be unpredictable and diverse. Drugs have been shown to induce virtually the whole gamut of human liver pathology from acute fulminant hepatitis to chronic active hepatitis to cirrho­ sis and even malignancy. Hence the possibility of adverse drug effects must be considered in the differential diagnosis of many patients with liver disease. This is well recognized and is very important; indeed, removal of the offending agent can often lead to reversal of the adverse effect. This is an area of hepatology where we can really make a difference.

Editors and Affiliations

  • Department of Pathology Division of Experimental Pathology, University of Toronto, Toronto, Canada

    Ross G. Cameron

  • Department of Clinical Biochemistry Banting Institute, University of Toronto, Toronto, Canada

    George Feuer

  • Parke-Davis Pharmaceutical Research Division Department of Pathology and Experimental Toxicology, Warner Lambert Company, Ann Arbor, USA

    Felix A. Iglesia

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation